Showing results (461-470 of 738) with videos related to
Sort By:
Pageof 74
The Lancet. Oncology|December 1, 2023
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trialBradley J Monk, Takafumi Toita, Xiaohua Wu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2023
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket StudyYoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2023
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial CancerIgnace Vergote, Jose Alejandro Pérez-Fidalgo, Erika Paige Hamilton, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2020
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary PeritoneumBradley J Monk, Rachel N Grisham, Susana Banerjee, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2025
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without <i>BRCA</i> MutationPanagiotis A Konstantinopoulos, Jae Weon Kim, Gilles Freyer, et al.Lancet (London, England)|April 13, 2026
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 studyNicoletta Colombo, Emese Zsiros, Gabriella Parma, et al.The New England Journal of Medicine|September 29, 2019
Niraparib in Patients with Newly Diagnosed Advanced Ovarian CancerAntonio González-Martín, Bhavana Pothuri, Ignace Vergote, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2019
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian CancerKrishnansu S Tewari, Robert A Burger, Danielle Enserro, et al.The New England Journal of Medicine|March 27, 2023
Dostarlimab for Primary Advanced or Recurrent Endometrial CancerMansoor R Mirza, Dana M Chase, Brian M Slomovitz, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2024
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trialB J Monk, M P Barretina-Ginesta, B Pothuri, et al.Pageof 74